Appointment

Claus Sundgreen
#Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints neuroscience leader as CMO

NRG Therapeutics has announced the appointment of Dr Claus Sundgreen as Chief Medical Officer (CMO), effective from 1 August 2026.  A recognised leader in neuroscience drug development with expertise in ALS, Dr Sundgreen brings over 25 years of clinical leadership with experience spanning translational medicine and all… Read More

#News

Neurons in the brain
#Amyotrophic lateral sclerosis (ALS) #Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints Paul Thompson as CDO

NRG Therapeutics has expanded its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).  In his role at NRG, Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.   NRG5051 is an oral,… Read More

#News

#Appointment #Drug discovery #New appointment

Drug discovery’s senior appointments: Q2 2025

Here, we provide an overview of the c-level moves that have taken place within the industry between April and June 2025. The ABPI has confirmed that Russell Abberley is the latest President-elect. Abberley, Vice President and General Manager of Amgen UK and Ireland, formally took up the Presidency on 13… Read More

#News

Russell Abberley
#Appointment #Association of the British Pharmaceutical Industry #Biopharmaceuticals #UK

ABPI announces new president-elect

The Association of the British Pharmaceutical Industry (ABPI) has announced that Russel Abberley, the Vice President and General Manager of Amgen UK and Ireland, will become the organisation’s new president, after having held the role on an interim basis.   Abberley will take up the role on 13… Read More

#News

New appointment
#Appointment #Career #Drug discovery #New appointment

C-level moves within drug discovery and development

We round-up the key senior career moves in the industry over the last few months. Emile Shaffu, Director of Sales, Newcells Biotech: Shaffu has over 20 years of international sales and management experience in the life sciences, most recently as UK Regional Business Manager at Bionano… Read More

#News

#Appointment #Career #Drug discovery #New appointment

Senior level moves within drug discovery

There have been a significant number of changes in c-level positions within the industry over the last two months. Dale Levitzke, Chief Executive Officer, and Curtis Nicholson, Director of Sales for Europe, Middle East, and Africa (EMEA), Sphere Fluidics: Levitzke brings over 25 years’ experience in… Read More

#News

#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

The last couple of months has seen a number of changes in senior roles in the drug discovery sector. Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma,… Read More

#Business & Investment #News

New appointments
#Appointment #Career #New appointment #Recruitment

The latest c-level appointments in drug discovery

Despite December usually being a slower time for recruitment, there has been a high number of senior moves within the drug discovery sector over the last three months. Shorla Oncology has appointed Rayna Sethi Herman as Chief Commercial Officer. Herman leaves a role as CCO at… Read More

#News

New appointments
#Appointment #Drug discovery #New appointment

Drug discovery’s senior appointments for Q4

Keep up to speed with the sector’s top executive appointments with DDW’s regular recruitment round-up. Kimryn Rathmell  has been chosen as the 17th director of the National Cancer Institute (NCI), bringing her experience as leader of the Department of Medicine at the Vanderbilt University Medical Center… Read More

#News

Human cell
#Appointment #Biotech #Drug discovery #Single-cell analysis

Cytomos appoints new director to assist commercialisation strategy  

Biotech company Cytomos has appointed a new Non-Executive Director in a bid to help accelerate plans to brings its cell analysis technology to market.   Dr Sharon Brownlow has joined as Non-Executive Director and will play a key role in helping Cytomos bring its Dielectric Spectroscopy (CDS)… Read More

#News

Job hire
#Appointment #Drug development #Europe

Norgine appoints new COO to drive European position  

Specialist pharmaceutical company Norgine has appointed Saulo Martiniano as its new Chief Operating Officer (COO).  Martiniano previously worked at L’Oréal and was responsible for leading Global Manufacturing Excellence across 38 plants that included more than 10,000 employees.  Martiniano will now be based in the UK and… Read More

#News

New appointments
#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

It’s not unusual for such a dynamic industry to have regular shake-ups in senior leadership, especially as innovative new technologies create brand new roles. The last couple of months have seen a number of high-profile job moves in drug discovery. Dr Robert Kirby, COO and Dr Edward Stevens,… Read More

#Business & Investment #News

#Appointment #Drug discovery #Life sciences #New appointment

Drug discovery’s top-level movers and shakers

It’s been another busy month for senior appointments in the drug discovery sector. David Favre, Chief Development Officer, SpliceBio Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry. He joins SpliceBio from Innoskel,… Read More

#News

New appointment
#Appointment #Drug discovery #Life sciences #New appointment

12 key industry appointments

A round-up of the top senior appointments in the drug discovery sector over the last month. Renos Savva, Head of Innovation, Discovery Park Savva’s previous experience includes co-founding Domainex, recognised by the Financial Times in 2018 as the ‘fastest-growing drug discovery contract research… Read More

#News

New appointments
#Appointment #Drug discovery #Life sciences #New appointment #Pharmaceutical industry

March’s key industry appointments

A round-up of the latest senior appointments in the drug discovery sector over the last month. Julian Collins, Jana Windt and Michiel Stork, ProBioGen Julian Collins has been appointed as Senior Vice President, Head of People & Organizational Development (P&OD) and a member of the Executive Team. Michiel Stork… Read More

#Business & Investment #News